Our highly innovative, next-generation gene editing platform offers a large and diverse collection of novel RNA-guided nucleases (RGNs) and base editors that provide flexible editing and unprecedented access to the genome.
Genome editing technologies, which allow genetic material to be removed, added, or altered at a specific location in the genome, have revolutionized the way cell and gene therapies and regenerative medicines are discovered and developed. However, these technological approaches depend on access to novel RGNs and base editors offering greater specificity and broader genome coverage.
We have one of the world’s largest and most diverse arrays of novel RGNs and base editors active in mammalian cells. They were developed using a proprietary collection of non-pathogenic microbes, which offers gene editing tools with higher fidelity, novel functionality, reduced immune response risk, and easier delivery.
Our genome editing platform is derived from AgBiome’s proprietary collection of tens of thousands of microbes. We retain access to this growing microbial collection to mine for gene editing systems with uses in human therapeutics.
We are a next-generation gene editing company focused on strengthening our platform, developing a pipeline of therapies for genetic diseases, and sharing our expertise through strategic partnerships.
Our Business ModelRead a deep dive from Life Edit technology development scientists on the diversity and versatility of our platform, what differentiates it from other gene editing technologies, and our distinctive culture of science.
Learn More
Large and diverse library of RNA-guided nucleases including Type II and Type V systems that encompass knock-out and knock-in capabilities, transcriptional regulation, and base editing when coupled with one of our proprietary deaminases.
Our nuclease collection has a broad range of Protospacer Adjacent Motifs (PAMs), short sequences that must accompany the DNA sequence for the enzyme to edit a gene, which offer unprecedented access to genomes.
We have identified several classes of DNA modifying enzymes including novel deaminases that can edit cytidine (C) or adenine (A).
Many of our RGNs are smaller than widely used CRISPR-Cas systems, offering ease and flexibility for in vivo delivery.
Our platform enables ex vivo engineering for cell therapies and regenerative medicines.
